Using a laser to take apart a lens clouded by cataracts can make the surgery easier and more precise, doctors reported on Wednesday. Reuters Health Information
Cochrane Review Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion
Central retinal vein occlusion (CRVO) is a common retinal vascular disorder in which macular edema (ME) may develop, with a consequent reduction in visual acuity. The visual prognosis in CRVO-ME is poor in a substantial proportion of patients, especial…
Behind the headlines New laser treatment for cataracts
The multiple parts to this research have been well-reported and produce a logical story of why these researchers believe this innovation to be an improvement on the current techniques that are used. They mention a few limitations, some of which revolve…
National Science Foundation Awards Grant To Zone24x7 And SRI International To Advance Tactile Devices For The Visually Impaired
Zone24x7 and SRI International have received a grant from the National Science Foundation (NSF) to determine the technical feasibility of incorporating SRI’s electroactive polymer artificial muscle (EPAM™) technology into a low-cost, mobile device th…
Regeneron Schedules November 22, 2010 Teleconference And Webcast To Discuss Results Of Two Phase 3 Studies With VEGF Trap-Eye In Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, November 22, to discuss results of two Phase 3 studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration, VIEW …
Regeneron Schedules November 22, 2010 Teleconference And Webcast To Discuss Results Of Two Phase 3 Studies With VEGF Trap-Eye In Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, November 22, to discuss results of two Phase 3 studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration, VIEW …